ADVANCED MALIGNANT SOLID NEOPLASM

This study tests whether adding panitumumab to sotorasib works better than sotorasib alone for people with advanced solid tumors that have a specific KRAS G12C mutation. About 105 adults with cancers that have spread will be randomly assigned to one of two groups. The goal is to …

This study tests a drug called erdafitinib in people with advanced cancers that have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that haven't responded to other treatments…

This early-stage trial tests FID-007, a reformulated version of the chemotherapy drug paclitaxel, in 50 adults with advanced solid tumors that have stopped responding to standard treatments. The drug is wrapped in a special polymer to help it reach deeper into tumors while avoidi…

This early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific genetic changes. The goal was to find the best dose and check for side effects, while seeing if the combination could shrink or s…

This early-phase study tests two oral drugs, ZEN003694 and binimetinib, together in people with advanced solid tumors that have RAS gene changes or triple-negative breast cancer. The goal is to find the safest dose and understand side effects. About 42 adults whose cancer has spr…

This early-phase study tests a drug called neratinib combined with one of three other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have not responded to standard treatments. The tumors must have certain gene changes (EGFR, HER2, HER3, H…

This study tests a drug called trametinib in 50 patients whose cancers have a specific genetic change called an NF1 mutation. The drug blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing.

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…

This study tests a drug called ipatasertib in people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the drug can shrink…

This study tests the drug olaparib in people with advanced solid tumors (including brain tumors and bile duct cancer) that have IDH1 or IDH2 mutations. The goal is to see if olaparib can shrink or slow the growth of these cancers. About 89 participants will receive the drug, and …

This study tests a drug called afatinib in 40 patients whose advanced cancers have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or slo…

This study tests a drug called afatinib in people with advanced cancers (excluding certain lung cancers) or lymphomas that have a specific change in the EGFR gene. The drug blocks signals that make cancer cells grow. The goal is to see if it can shrink or slow tumors in patients …

This study tested the drug crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink or stop the growth of these tumors. Only 5 patients took part, and the study is no longer enrolling new…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. …

This study tests a drug called osimertinib in people with advanced cancers that have specific EGFR gene mutations. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or slow the disease. The trial includes 19 adults with vario…

This study tests a drug called MLN0128 (TAK-228) in 35 adults with advanced cancers that have a specific genetic change (mTOR mutation). The drug works by blocking certain enzymes that cancer cells need to grow. The main goal is to see if the drug can shrink or stop the cancer fr…

This study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…

This study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF gene mutations or fusions. The goal was to see if trametinib could shrink tumors or stop them from growing by blocking certain proteins. The trial is no longer recruiting, and results…

This study tests a drug called ado-trastuzumab emtansine in people with advanced cancers that have too many HER2 receptors (HER2 amplification), except breast and stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Rese…

This study tests a combination of three drugs (copanlisib, nivolumab, and ipilimumab) in adults with advanced solid tumors that have specific gene changes (PIK3CA or PTEN). The goal is to see if adding copanlisib to standard immunotherapy works better at controlling tumor growth.…

This early-stage trial tests two experimental drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The main goal is to find the safest and most effective dose by monitoring side effects. About 121 participants will take part …

This study tested a drug called AZD5363 in 35 people with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…

This early-phase trial tests a new treatment that uses tiny particles to deliver genetic material that shuts down a gene linked to cancer growth. The study includes 49 adults with advanced solid tumors that have spread or returned. The main goal is to find the safest dose and und…

This early-phase trial tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, bladder, …

This study tested the drug ensartinib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers had come back or stopped responding to treatment and had specific gene changes (ALK or ROS1). The goal was to see if the drug could shrink o…

This study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had spread, returned, or stopped responding to treatment. The drug targets tumors with specific changes in FGFR genes. The main goal was to see if the drug could shrink or stop t…

This study tests a drug called AZD1775 in people with advanced cancers that have a BRCA gene mutation. The drug blocks a protein that cancer cells need to grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with various solid tum…

This study tests a drug called larotrectinib in 35 people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug blocks a faulty protein that helps cancer cells grow. The goal is to see if the drug can shrink tumors or stop the cancer from sprea…

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced or hard-to…

This study tests two targeted drugs, dabrafenib and trametinib, in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a BRAF V600 mutation. The drugs block proteins that help cancer grow. The goal is to see if the combination can shrink tumors or stop them …

This study tests a drug called copanlisib in 35 adults with advanced or treatment-resistant cancers that have a specific change in the PTEN gene. The drug blocks a faulty protein that helps cancer cells grow. The goal is to see if it can shrink tumors or stop them from growing fo…

This study tests a drug called telaglenastat (CB-839) that blocks an enzyme tumors need to grow. It is for people with advanced solid tumors or malignant peripheral nerve sheath tumors that have certain gene mutations (NF1, KEAP1/NRF2, or LKB1). The goal is to see if stopping the…

This study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. About 49 participants will receive the drug to see if it can shrink tum…

This study is for people with advanced cancers that have a specific genetic change called an NF2 mutation. The drug defactinib blocks a protein that may help these cancers grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults are t…

This study tests the drug crizotinib in people with advanced or treatment-resistant solid tumors, lymphoma, or multiple myeloma that have a specific genetic change called MET amplification. Crizotinib works by blocking signals that help cancer cells grow and spread. The main goal…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to adults with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find a dose that limits side effects while pot…

This study tests a drug called palbociclib in people with advanced cancers that have specific genetic changes (CCND1, 2, or 3 amplification). The drug blocks certain proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from growing. About 4…

This study tests a drug called taselisib in 70 people with advanced cancers (except breast cancer) that have a specific genetic change called PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors …

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. The drug works by blocking signals that make cancer cells grow. The goal is to see if the tumors shrink or stop growing. About 10 adults with various cancers (but not…

This study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific changes in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug ca…

This study tests a drug called crizotinib in 20 adults with advanced cancers that have a specific genetic change called MET exon 14 deletion. The drug works by blocking enzymes that help cancer cells grow and spread. Researchers want to see if it can shrink tumors or stop them fr…

This study tests a drug called GSK2636771 in people whose cancers have lost a gene called PTEN. The drug blocks a protein (PI3K-beta) that helps these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing. About 35 adults with advanced…

This early-phase trial tested a combination of three drugs—dasatinib, temsirolimus, and cyclophosphamide—in 14 children and young adults with advanced solid tumors that had spread, returned, or stopped responding to standard treatments. The main goals were to find the safest dose…

This study tested the drug trametinib in 4 people with advanced cancers that have GNAQ or GNA11 mutations. Trametinib blocks certain proteins that help these cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing.

This early-phase trial tests a combination of three drugs (copanlisib, olaparib, and durvalumab) in 39 adults with advanced solid tumors that have spread or cannot be removed. The goal is to find the safest dose and see how well the drugs work together. Participants must have spe…

This study tests whether adding a drug called methoxyamine (TRC102) to standard chemotherapy can help shrink tumors in people with advanced solid tumors or mesothelioma that have not responded to other treatments. The goal is to make cancer cells more sensitive to chemo. About 30…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …

This study tests a drug called binimetinib in 53 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NRAS mutation. The drug blocks proteins that help cancer grow. The main goal is to see if the drug can shrink tumors or stop…

This study tests a drug called ulixertinib in 35 adults with advanced cancers that have certain BRAF gene changes (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. The main goal is to see how many patients' tumors shrink or disappear. This i…

This study tests a drug called GSK2636771 in 24 adults with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growin…

This study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …

This early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a cell-growth blocker)—in people with advanced solid tumors that have a HER2 mutation. The study first finds the safest dose, then compares the combo against…

This study tests a combination of three drugs (niraparib, temozolomide, and atezolizumab) in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the safest dose and see if the combination helps keep the cancer from growing longer than …

This study tests a pill called palbociclib in people with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug blocks signals that make cancer cells multiply. Researchers want to see if it can shrink tumors or stop them from growing for at least 6 months. A…

This study tests a drug called pembrolizumab in 157 people with rare tumors that cannot be removed by surgery or have spread. The drug helps the immune system fight cancer by blocking a protein that slows it down. The main goal is to see if the drug can stop tumors from growing f…

This study is testing whether the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called a ROS1 translocation. The trial includes patients with various advanced solid tumors, lymphoma, or multiple myeloma that have not respond…

This study is testing a mindfulness program that has been adapted for Latino cancer patients and their family caregivers. The goal is to see if it helps reduce stress and anxiety and improves mental well-being. About 68 patient-caregiver pairs are taking part, and the program foc…

This study tests a virtual group therapy program for caregivers of people with advanced cancer or serious life-limiting illness. The therapy helps caregivers connect to meaning and purpose, aiming to reduce feelings of hopelessness and burden. The study will enroll 80 caregivers …

This study compares two drugs, olanzapine and megestrol acetate, to see which works better for improving appetite and preventing weight loss in people with advanced cancer. About 227 patients will take one of the two medications for four weeks. The goal is to find a more effectiv…

This study tests whether a technology-enhanced symptom monitoring program, used alongside regular clinic visits and remote check-ins, can improve quality of life for people with advanced solid tumors who are also in phase 1 immunotherapy trials. About 119 participants will use th…

This study tests whether an open labeled placebo—a pill that patients know contains no active drug—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply believing in treat…

This study tests whether adding a steroid drug called dexamethasone to a physical activity program can better reduce severe fatigue in people with advanced cancer. About 99 participants will be assigned to exercise alone or exercise plus the drug. The goal is to see if the combin…

This study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can lessen severe fatigue in people with advanced solid tumors that have spread or come back. About 129 participants will receive the drug and support for several weeks.…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…

This study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…

This study looks at two different ways to provide palliative care—a type of care that helps with symptoms and stress—to people with advanced cancer and their caregivers. About 208 patients and their caregivers will take part. The goal is to see which method helps more patients co…

This study measures how often cancer patients in a supportive care clinic experience cachexia (unintentional weight loss and appetite loss) and examines the emotional toll on both patients and their primary caregivers. Researchers will track weight changes and use questionnaires …

This early-phase study looks at how the drug DS-8201a affects tumor cells and the immune system in people with advanced HER2-positive cancers that have stopped responding to standard treatments. Researchers will take small tumor samples before and after treatment to measure chang…

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will take part, and their doctors will either use the t…

This study surveys 117 advanced cancer patients to learn if they have talked with family about managing their social media accounts after death. The goal is to understand patient needs and reduce stress around digital legacy. Participants are adults who have used social media and…